Could a common diabetes pill slow kidney decline in dialysis patients?

NCT ID NCT05715814

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen May 07, 2026 · Last updated May 24, 2026 · Updated 1 time

Summary

This study tests whether a daily 25 mg dose of empagliflozin, a drug typically used for diabetes, is safe and can help preserve the small amount of kidney function still present in people on peritoneal dialysis. About 20 adults with end-stage kidney disease who produce at least 250 ml of urine daily will take the drug for a period, and researchers will measure changes in kidney function and dialysis effectiveness. The goal is to see if this approach can delay further kidney decline without causing serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY DYSFUNCTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Toronto General Hospital
RECRUITING

Toronto, Ontario, M5G2N2, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

END STAGE KIDNEY DISEASE KIDNEY DYSFUNCTION PERITONEAL DIALYSIS COMPLICATION RESIDUAL KIDNEY FUNCTION SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS